Multicenter evaluation of the Selux Next-Generation Phenotyping antimicrobial susceptibility testing system
Journal of Clinical Microbiology · 17.01.2024 · 62 (1)
DOI: 10.1128/jcm.00546-23 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 17.01.2024. Verfasst von Kristin R Baker und 39 weiteren Autor:innen. Beteiligte Einrichtung: Selux Diagnostics, Charlestown, Massachusetts, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Anti-Infective Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ASPR AND BARDA.
Abstract (Originalsprache)
The Selux Next-Generation Phenotyping (NGP) system (Charlestown, MA) is a new antimicrobial susceptibility testing system that utilizes two sequential assays performed on all wells of doubling dilution series to determine MICs. A multicenter evaluation of the performance of the Selux NGP system compared with reference broth microdilution was conducted following FDA recommendations and using FDA-defined breakpoints. A total of 2,488 clinical and challenge isolates were included; gram-negative isolates were tested against 24 antimicrobials, and gram-positive isolates were tested against 15 antimicrobials. Data is provided for all organism-antimicrobial combinations evaluated, including those that did and did not meet FDA performance requirements. Overall very major error and major error rates were less than 1% (31/3,805 and 107/15,606, respectively), essential agreement and categorical agreement were >95%, reproducibility was ≥95%, and the average time-to-result (from time of assay start to time of MIC result) was 5.65 hours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Selux Diagnostics, Charlestown, Massachusetts, USA.
- Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, USA.
- Clinical Microbiology Institute (CMI), Wilsonville, Oregon, USA.
- IHMA, Schaumburg, Illinois, USA.
- JMI Laboratories/Element, North Liberty, Iowa, USA.
- Element, Acton, Massachusetts, USA.
ORCID-Profile: Kristin R Baker, Dee Shortridge, Virginia M Pierce, Eric Stern
Förderung
- ASPR AND BARDA
Zitieren
APA
Baker, K. R., Flentie, K., Spears, B. R., Mozharov, S., Roberts, K., El Ganbour, A., Somers, M., Calkwood, J., Liu, J., DaPonte, K., Sam, N., Kaur, G., Chen, F., Donato, J., Chao, A., Lewis, A., Sherman, J., Mortimer, K., Harrington, A. T., …, & Stern, E. (2024). Multicenter evaluation of the Selux Next-Generation Phenotyping antimicrobial susceptibility testing system. Journal of Clinical Microbiology, 62(1). https://doi.org/10.1128/jcm.00546-23
Vancouver
Baker KR, Flentie K, Spears BR, Mozharov S, Roberts K, El Ganbour A, et al. Multicenter evaluation of the Selux Next-Generation Phenotyping antimicrobial susceptibility testing system. Journal of Clinical Microbiology. 2024;62(1). doi:10.1128/jcm.00546-23
BibTeX
@article{Baker2024,
author = {Baker, Kristin R and Flentie, Kelly and Spears, Benjamin R and Mozharov, Sergey and Roberts, Kristen and El Ganbour, Asmae and Somers, Mark and Calkwood, John and Liu, Jamie and DaPonte, Kayla and Sam, Nikitha and Kaur, Gurleen and Chen, Felicia and Donato, Jonathan and Chao, Alan and Lewis, Autumn and Sherman, Jingzi and Mortimer, Karen and Harrington, Amanda T and Traczewski, Maria and Carpenter, Darcie and Shortridge, Dee and Lindley, Jill and Diep, Alexander and Norton, Emmet and Green, Matt and Gajewski, Joe and Landrith, Rebecca and Nalubega, Fatuma and McCallum, Justin and Beiswenger, Melissa and Dolan, Brittany and Brennan, Kathleen and Carpenter, Afton and Vacic, Aleksandar and Flyer, Alec N and Pierce, Virginia M and Hooper, David C and Lewis Ii, James S and Stern, Eric},
title = {Multicenter evaluation of the Selux Next-Generation Phenotyping antimicrobial susceptibility testing system},
journal = {Journal of Clinical Microbiology},
year = {2024},
volume = {62},
number = {1},
doi = {10.1128/jcm.00546-23}
}
EUVIMED